The Medtech Compliance Forum by Aurevia & RAPS is a dedicated platform within Labquality Days, bringing together regulatory, quality, clinical and technical perspectives to address the real-world challenges facing the medtech industry.
We asked Mika Siitonen, Operations Manager, Digital Health at Aurevia, and the lead for the Medtech Compliance Forum, to explain the thinking behind the collaboration and, above all, what it offers regulatory professionals and medtech companies.
“Regulatory professionals rarely suffer from a lack of information. There is plenty of it, even too much."
The real challenge is understanding what matters, what it means in practice, and what should be done next. And how to remain in control of the bigger picture.
"Having worked in this field for so many years, I know that none of us has all the answers. Regulation is changing and expanding quickly, technologies are becoming more complex, and expectations continue to grow. At the same time, regulatory and quality professionals are expected to protect patients, support innovation, keep all the moving parts under control and help their organisations move forward.
That is why collaboration matters.
For RAPS, the collaboration creates a stronger connection with the Nordic medtech community building on the 50-year history and established network of Labquality Days and its medtech tracks.
For Aurevia, it creates a more direct bridge between our regional ecosystem and the global regulatory community.
But the real value is not what this collaboration brings to either organisation. It is what it brings to the people and companies we serve.
For me, the value lies in bringing an even broader range of international regulatory thinking into the conversation and connecting it with the questions companies are dealing with every day: What evidence will be sufficient? How should new technologies be approached? What will authorities and notified bodies expect? And how can we make responsible decisions when the regulatory path is still evolving or uncertain?
Bringing this level of international expertise together under one roof in the Nordics is valuable in itself. Participants will not only hear these experts speak, but also have the opportunity to continue the conversation beyond the presentations, ask questions, compare perspectives and gain insights that are difficult to obtain from guidance documents or webinars alone. Just as importantly, the Forum creates an opportunity to build genuine connections with experts and peers who are working through many of the same challenges.
By bringing regulatory, quality, clinical and technical perspectives into the same conversation, the Forum allows us to examine different interpretations, share practical experience and discuss openly both what we know and where uncertainty still remains.
This is the thinking behind the Medtech Compliance Forum by Aurevia & RAPS, part of Labquality Days in Helsinki.
We want to create a place where global regulatory insight meets the Nordics on a larger scale, and where regulatory excellence becomes part of how companies make better decisions, build safer products, grow stronger and achieve sustainable access to international markets.
I am genuinely proud that we are building this together.
I hope the Forum becomes a place where regulatory professionals do not simply receive more information, but leave with greater clarity, useful connections and a better understanding of what to do next.”
Learn more and secure your spot
What is the Medtech Compliance Forum by Aurevia & RAPS?
The Medtech Compliance Forum by Aurevia & RAPS is a dedicated part of Labquality Days for professionals across the medtech field. The forum focuses on compliance, regulatory strategy, evidence requirements, and practical challenges throughout the product lifecycle in a rapidly evolving field.
We warmly welcome medtech and healthtech professionals, medical device manufacturers, regulatory experts, quality leaders, and innovators to join us in 2027 and help shape the future of health technology.
See the full press release.
Share this article
